Status:
COMPLETED
Smoking Cessation Assistance With LIBERTAL, A Phospholipid Mixture
Lead Sponsor:
Kaplan Medical Center
Collaborating Sponsors:
Modus Biological Membranes, Ltd.
Conditions:
Smoking
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
It has been shown in rodent models that chronic substance abuse is associated with a rigidification of cell membrane fluidity due to a change in the membrane cholesterol/phospholipids ratio. Upon subs...
Detailed Description
A randomized,double-blind, dose-finding,phase IIB study with Libertal has been performed in 493 volunteer smokers, wishing to quit. They were divided into 5 arms: 4 treatment groups of 0.5, 1.0, 2.0 a...
Eligibility Criteria
Inclusion
- Smokers of at least 1 year duration
- Smoking at least 10 cigarettes/day
- Having failed at least one previous smoking cessation effort.
- Without a major cardio-vascular or metabolic disease or condition.
Exclusion
- An uncontrolled major cardiovascular, metabolic, or other condition condition.
- Need for surgery during the period of participation in the trial.
- Any treatment for smoking cessation during the 2 months preceding enrollment in the present trial.
Key Trial Info
Start Date :
February 1 2002
Trial Type :
INTERVENTIONAL
End Date :
July 1 2002
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00317213
Start Date
February 1 2002
End Date
July 1 2002
Last Update
April 14 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Arazi Clinic and Modus Clinic
Tel-Aviv and Rehovot, Israel